|1.||Havekes, Louis M: 6 articles (05/2008 - 01/2004)|
|2.||Berbée, Jimmy F P: 5 articles (01/2011 - 02/2005)|
|3.||Rensen, Patrick C N: 5 articles (01/2011 - 02/2005)|
|4.||Wang, Jiaxiang: 3 articles (01/2014 - 08/2010)|
|5.||Zheng, Shu: 3 articles (01/2014 - 08/2010)|
|6.||Gautier, Thomas: 3 articles (06/2012 - 04/2008)|
|7.||Björkegren, Johan: 3 articles (01/2011 - 09/2002)|
|8.||Yu, Jiekai: 2 articles (01/2014 - 08/2010)|
|9.||Abildayeva, Karlygash: 2 articles (01/2011 - 04/2008)|
|10.||Hansen, John-Bjarne: 2 articles (01/2011 - 07/2008)|
|1.||Coronary Artery Disease (Coronary Atherosclerosis)
06/01/2012 - "Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease."
01/28/2011 - "Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease."
01/25/2000 - "Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease."
07/01/2008 - "Previous studies have shown that postprandial triglyceride-rich lipoproteins (TRLs) are enriched with apolipoprotein-C-I (apoC-I) in healthy individuals with increased intima-media thickness and in patients with coronary artery disease. "
09/01/2002 - "Recently, we reported that exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease is associated with enrichment of remnant lipoproteins with apolipoprotein C-I (apoC-I). "
01/01/1998 - "Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1."
12/01/1998 - "Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice."
01/01/2011 - "The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis."
02/01/2005 - "Studies in humans and mice have shown that increased expression of apolipoprotein C-I (apoC-I) results in combined hyperlipidemia with a more pronounced effect on triglycerides (TGs) compared with total cholesterol (TC). "
|3.||Atherosclerotic Plaque (Atheroma)
01/01/2008 - "We found that the apolipoprotein C1 (apo C1) gene was prominently expressed in the atheroma of the carotid and femoral arteries, as compared to the nonatherosclerotic arteries. "
03/01/2007 - "Our studies suggest a potential role for the signal transduction pathway involving apolipoprotein C-I for in vivo apoptosis and atherosclerotic plaque rupture visualized by MRI."
01/01/2008 - "Apolipoprotein C1 and apolipoprotein E are differentially expressed in atheroma of the carotid and femoral artery."
03/22/2005 - "Future studies of the in vivo role of apolipoprotein C1 might provide additional insights into the infection process of HCV."
10/01/2008 - "We investigated the involvement of apolipoprotein C1 (ApoC1) in HCV infection in the HCV pseudotyped particle system (HCVpp), in the recently developed cell culture infection model (HCVcc), and in authentic HCV isolated from viremic chimpanzees. "
|1.||Apolipoproteins C (ApoC)
|6.||Biological Markers (Surrogate Marker)
|9.||Apolipoprotein B-100 (Apo B 100)